Source comparison
Thymosin Alpha-1 Thymalin Protocol Thymus Research: Evidence Comparison
Thymosin Alpha-1 TLR9 agonist → dendritic cell activation → Th1 polarisation Toll-like receptor 9 on dendritic cells and macrophages Hepatitis B/C viral clearance (University of Texas), vaccine response enhancement (NIH), sepsis immune recovery (Johns Hopkins)
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 agonist → dendritic cell activation → Th1 polarisation
- Toll-like receptor 9 on dendritic cells and macrophages
- Hepatitis B/C viral clearance (University of Texas), vaccine response enhancement (NIH), sepsis immune recovery (Johns Hopkins)
- 1.6–3.2mg subcutaneous every 72–96 hours
- 4–8 week cycles with 2-week washout
- Proven immune activation mechanism with narrow dosing window. Twice-weekly pulsed protocols outperform daily dosing due to receptor desensitisation kinetics
- Thymalin
- Glucocorticoid receptor antagonist → thymic preservation → T-cell precursor protection
- Glucocorticoid receptors in thymic epithelial cells
- Age-related thymic involution (Russian Academy of Medical Sciences), stress-induced immunosuppression, corticosteroid co-administration models
- 5–20mg intramuscular or subcutaneous daily
- 5–10 day on / 10–14 day off cycles
- Effective for stress/aging contexts but requires morning dosing alignment with cortisol circadian rhythm. Continuous protocols beyond 10 days trigger HPA axis compensation
- Combined Protocol
- Dual pathway: immune activation + thymic preservation
- TLR9 (Tα1) + glucocorticoid receptors (thymalin)
- Aging + infection models, chemotherapy immunoprotection, chronic viral infection with stress
- Tα1 1.6mg evening + thymalin 10mg morning on alternating schedules
- 6-week intervention with staggered dosing
- Theoretically synergistic but limited published evidence. Staggered timing prevents pharmacodynamic interference and optimises circadian alignment for both mechanisms